June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.
But pressure is on the shingles vaccine as the consumer spin-off approaches.
Interim results on bleeds look impressive, but more data are needed to gauge efanesoctocog alfa's chances against Roche's Hemlibra.
Novel approaches including gene editing are creeping towards approval.
March Pdufa dates are set for relatlimab as well as Akebia’s vadadustat, while Amylyx’s ALS drug heads for a panel.
How can the company wring the most value from Pyrukynd?
Will upping the dose and changing the primary endpoint pay off?